Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Benefits of Optimizing Antipsychotic Doses and Their Relationship to Dopamine D2 Receptor Occupancy in Older Persons With Schizophrenia
This study is currently recruiting participants.
Study NCT00716755 Information provided by Centre for Addiction and Mental Health
First Received: July 14, 2008 Last Updated: July 7, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorder
Delusional Disorder
Psychotic Disorder
Additional conditions recognized in this trial
Delusions
Disease
Psychotic Disorders
Schizophrenia, Paranoid
More general conditions related to this trial
Behavioral Symptoms
Mental Disorders
Pathologic Processes
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
Risperidone and PET scans
Additional drug interventions recognized in this trial
Antipsychotic Agents
Dopamine
Dopamine Agents
Risperidone
More general drug interventions related to this trial
Autonomic Agents
Cardiotonic Agents
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Sympathomimetics
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Centre for Addiction and Mental Health
Back to top of Main Content
